NCT00239629已完成4 期
Differential Effects of Teriparatide and Strontium Ranelate on Bone Remodeling and Formation in Postmenopausal Women With Osteoporosis
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 73
- 试验地点
- 12
- 主要终点
- The primary efficacy measure is the mineralization surface (MS%BS) evaluated in double tetracycline stained bone biopsies.
研究概览
简要总结
The aim of this study is to directly compare the bone forming effects of 20 microg/day of teriparatide with those of 2 g/day strontium ranelate as measured by the histomorphometric variables and biochemical bone formation markers after 6 months of therapy in postmenopausal women with osteoporosis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 45 Years 至 90 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
The primary efficacy measure is the mineralization surface (MS%BS) evaluated in double tetracycline stained bone biopsies.
次要结局
- Other routine histomorphometric parameters, measured at visits 2, 3, 4, and 5.
研究者
研究点 (12)
Loading locations...
相似试验
进行中（未招募）
不适用
Differential Effects of Teriparatide and Strontium Ranelate on Bone Remodeling and Formation in Postmenopausal Women with Osteoporosis: A Histomorphometric StudyEfectos diferenciales de la teriparatida y del ranelato de estroncio en el remodelado y la formación ósea en mujeres posmenopáusicas con osteoporosis: Estudio histomorfométrico - GHCXOsteoporosisEUCTR2005-000515-95-ESilly S.A.80
进行中（未招募）
不适用
Differential Effects of Teriparatide and Strontium Ranelate on Bone Remodeling and Formation in Postmenopausal Women with Osteoporosis: A Histomorphometric Study - GHCXOsteoporosisEUCTR2005-000515-95-CZEli Lilly and Company Limited68
进行中（未招募）
不适用
Differential Effects of Teriparatide and Strontium Ranelate on Bone Remodeling and Formation in Postmenopausal Women with Osteoporosis: A Histomorphometric Study - GHCXOsteoporosisEUCTR2005-000515-95-DEEli Lilly and Company Limited68
已完成
3 期
Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced OsteoporosisOsteoporosisNCT00051558Eli Lilly and Company428
已完成
4 期
Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone ResorptionPostmenopausal OsteoporosisNCT01750086Massachusetts General Hospital27